Insider Transactions in Q1 2022 at Exelixis, Inc. (EXEL)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
10,000
-3.58%
|
$220,000
$22.43 P/Share
|
|
Mar 31
2022
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.46%
|
$60,000
$6.21 P/Share
|
|
Mar 29
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
13,283
-2.15%
|
$292,226
$22.0 P/Share
|
|
Mar 28
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
4,717
-0.76%
|
$103,774
$22.0 P/Share
|
|
Mar 04
2022
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
59,490
+12.88%
|
-
|
|
Mar 04
2022
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
70,715
+20.8%
|
-
|
|
Mar 04
2022
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
67,875
+9.82%
|
-
|
|
Mar 04
2022
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
75,985
+15.02%
|
-
|
|
Mar 04
2022
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
270,415
+40.38%
|
-
|
|
Mar 02
2022
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Indirect |
50,000
-4.01%
|
-
|
|
Mar 01
2022
|
Alan M Garber Director |
SELL
Open market or private sale
|
Direct |
21,301
-40.41%
|
$447,321
$21.0 P/Share
|
|
Mar 01
2022
|
Alan M Garber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+43.14%
|
$120,000
$3.13 P/Share
|
|
Feb 25
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
31,238
-13.6%
|
$593,522
$19.53 P/Share
|
|
Feb 24
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
18,000
-3.14%
|
$360,000
$20.0 P/Share
|
|
Feb 22
2022
|
Carl B Feldbaum Director |
SELL
Open market or private sale
|
Direct |
20,000
-70.12%
|
$380,000
$19.49 P/Share
|
|
Feb 22
2022
|
Carl B Feldbaum Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+41.22%
|
$60,000
$3.13 P/Share
|
|
Feb 22
2022
|
Stelios Papadopoulos Director |
SELL
Open market or private sale
|
Direct |
84,515
-6.48%
|
$1,605,785
$19.56 P/Share
|
|
Feb 15
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
15,527
-3.18%
|
$279,486
$18.59 P/Share
|
|
Feb 15
2022
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,327
-2.48%
|
$329,886
$18.59 P/Share
|
|
Feb 15
2022
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
65,147
-17.28%
|
$1,172,646
$18.59 P/Share
|
|
Feb 15
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
12,226
-1.05%
|
$220,068
$18.59 P/Share
|
|
Feb 15
2022
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,177
-2.79%
|
$363,186
$18.59 P/Share
|
|
Feb 03
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
60,000
-19.66%
|
$1,020,000
$17.91 P/Share
|
|
Feb 03
2022
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+16.43%
|
$60,000
$1.9 P/Share
|
|
Jan 04
2022
|
Vicki L Goodman EVP, Prod Dev & Med Aff &CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,613
-3.05%
|
$144,647
$19.18 P/Share
|
|
Jan 04
2022
|
Vicki L Goodman EVP, Prod Dev & Med Aff &CMO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|